الفهرس 
Neonatal SepsisOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Background: Anemia is a serious public health problem affecting 2 billion people worldwide, particularly infants and young children in developing countries where its etiology is multifactorial.
Hepcidin inhibits the cellular efflux of iron by binding to, and inducing the degradation of ferroportin, the sole known iron exporter in iron transporting cells.
Aims: The aim of this study is to determine if Hepcidin could be used as a predictor for recurrent blood transfusions in septic preterm neonates and to study its relation to frequency and amount of packed RBCs transfusions.
Patients and Methods: This is a case- control study, conducted at Ain Shams NICUS from Novembre till 20th Decembre 2016. The study was conducted on 70 preterm neonates accordin to sample size calculation using EPI program using sensitivity of Hepcidin 70% + 10%, C.I 95% and power of the study 80%.
Results: 50 preterm neonates compromised the septic group while 20 preterm neonates compromised the control group.
Conclusion: Serum Hepcidin is higher in septic preterm neonates compared to non –septic preterm neonates, Morover it is higher in septic preterm neonates with frequent blood transfusion comapred to infrequent blood transfusion. Serum Hepcidin correlates with duration of hospital stay.
A cut-Off level of serum Hepcidin 7 ng/ml may be a good predictor for the need of frequent blood transfusion in septic preterm neonates.
Recommendations: Hepcidin may be used as a marker for prediction for need of frequent blood transfusion in septic preterm neonates so we can use single donor methods.
Further investigations are needed for more assessment of Hepcidine level and it’s correlation to need for blood transfusion and it’s frequency using more sample size and on different population and for longer durations.